Cardiac implantable electronic devices (CIED) are potentially life-saving treatments for several cardiac conditions, but are not without risk. Despite dissemination of recommended strategies for prevention of device infections, such as administration of antibiotics before implantation, infection rates continue to rise resulting in escalating health care costs. New trials conveying important steps for better prevention of device infection and an EHRA consensus paper were recently published. This document will review the role of various preventive measures for CIED infection, emphasizing the importance of adhering to published recommendations. The document aims to provide guidance on how to prevent CIED infections in clinical practice by considering modifiable and non-modifiable risk factors that may be present pre-, peri-, and/or post-procedure.
Atrial fibrillation (AF) is common and increases the risk for stroke and heart failure (HF). The early identification of patients at risk may prevent the development of AF and improve prognosis. This study, therefore, aimed to test the effect of the association between P-wave and PR-interval on the ECG and incident AF.The PIVUS (Prospective Investigation of the Vasculature in Uppsala Seniors) study (1016 individuals all aged 70 years; 50% women) was used to identify whether the ECG variables P-wave duration (Pdur) and PRduration in lead V1 were related to new-onset AF. Exclusion criteria were prevalent AF, QRS-duration "130 milliseconds (msec), atrial tachyarrhythmias and implanted pacemaker/defibrillator. Cox proportional-hazards models were used for analyses. Adjustments were made for gender, RR-interval, beta-blocking agents, systolic blood pressure, body mass index, and smoking.Of 877 subjects at risk, 189 individuals developed AF during a 15-year follow-up. There was a U-shaped relationship between the Pdur and incident AF (P = 0.017) following multiple adjustment. Values below 60 msec were significantly associated with incident AF, with a hazard ratio of 1.55 (95% confidence interval 1.15-2.09) for a Pdur !42 msec. There was no significant relationship between incident AF and the PR-interval.A short Pdur derived from the ECG in V1 may be a useful marker for new-onset AF, enabling the early identification of at-risk patients.
Background The implantation rates of cardiac implantable electronic devices have steadily increased, accompanied by a steeper rise of device related infections (DRI). Hypothesis The prevalence of DRI for cardiac resynchronization therapy (CRT) is higher in clinical practice than reported previously, even at a university hospital, and likely higher than reported to the national device registry. Methods Electronic medical records of consecutive patients undergoing a CRT procedure between January 2016 and December 2017 were analyzed. Clinical history, procedure related variables and complications were reviewed by specialists in cardiology and infectious diseases. Results A total of 171 patients, mean aged 74 years, 138 males (80.7%) were included. Twelve DRI occurred in 10 patients during mean 2.5 years follow‐up, giving a prevalence of 7% (incidence of 29/1000 person‐years). Reoperation, pocket haematoma, ≥3 procedures, previous device infection and indwelling central venous line were the strongest predictive factors according to univariate analysis. Out of 63/171 (36.8%) major complications, 31(49.2%) were lead‐related. There were 49/171 (28.7%) reoperations and 15/171 (8.8%) minor complications. The number major complications and DRI reported to the national device registry were 7/171 (4.1%) and 2/171 (0.6%), respectively, reflecting a 5‐fold underreporting. Conclusions The high rate of CRT device infections is in sharp contrast to those reported by others and to the national device registry. Although a center specific explanation cannot be excluded, the high rates highlight a major issue with registries, reinforcing the need for better surveillance and automatic reporting of device related complications.
Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): Uppsala University Hospital Background and purpose Early identification of patients at risk of congestive heart failure (HF) may potentially alter their poor prognosis. The aim was therefore to test whether the P-wave and PR-interval, simple non-invasive ECG measures reflecting systolic and diastolic atrial function, could predict incident HF. Methods The PIVUS (Prospective Investigation of the Vasculature in Seniors) study including all individuals aged 70 years (1016 individuals, 50% women) was used to identify predictors of HF. Subjects with prevalent HF, QRS duration ≥ 130 msec or atrial arrhythmias on baseline ECG were excluded. Cox proportional hazard analysis was used to relate P-wave duration (Pdur), amplitude (Pamp) and PR interval in lead V1, to incident HF. Adjustment was performed for gender, RR-interval, beta-blocking agents, systolic blood pressure, body mass index and smoking. Results A total of 107 of 836 (12,8%) subjects at risk, developed HF during 15 years follow-up. The multivariate analysis, showed a strong U-shaped correlation between Pdur and incident HF (p=0.0001), which was significant for a Pdur< 60 msec [HR 2.75 (95% CI 1.87-4.06) at Pdur 40 msec]. There was no significant relationship between incident HF and the PR-interval, or the Pamp. A Pdur<60 msec improved discrimination by 3.7% when added to the confounders described above (p=0.048). Conclusions A short P-duration, a simple and easy ECG measure, may potentially be a useful predictor of developing HF, enabling early detection and treatment of HF.
The incidence of supraventricular tachycardia during pregnancy is low. The tachyarrhythmias are often well tolerated but may become more frequent, refractory, and symptomatic, and may even manifest for the first time during pregnancy even in the absence of structural heart disease. Arrhythmia requiring treatment develops in up to 15% of patients with structural heart disease during pregnancy. Ventricular arrhythmias and symptomatic bradycardia are rare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.